Observations placeholder
Fabrazyme
Identifier
018984
Type of Spiritual Experience
Background
A variety of mutations in the GLA gene affect the synthesis, processing, and stability of an enzyme, which causes Fabry's disease, a rare lysosomal storage disorder and sphingolipidosis that results from a failure to catabolize alpha-D-galactosyl glycolipid moieties.
Two enzyme replacement therapies are available to functionally compensate for alpha-galactosidase deficiency. Agalsidase alpha and beta are both recombinant forms of the human α-galactosidase A enzyme and both have the same amino acid sequence as the native enzyme. Agalsidase alpha and beta differ in the structures of their oligosaccharide side chains
A description of the experience
Alpha-galactosidase is a glycoside hydrolase enzyme that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. It is encoded by the GLA gene] Two recombinant forms of alpha-galactosidase are called agalsidase alfa (INN) and agalsidase beta (INN).
On Dec, 14, 2015: 2,195 people reported to have side effects when taking Fabrazyme. Among them, 3 people (0.09%) have Hallucination.
On Dec, 14, 2015: 2,195 people reported to have side effects when taking Fabrazyme. Among them, 87 people (3.96%) have Death.
Time on Fabrazyme when people have Death :
< 1 month1 - 6 months6 - 12 months1 - 2 years2 - 5 years5 - 10 years10+ years Death5.88%11.76%11.76%23.53%23.53%23.53%0.00%